SCHEMBL2643816

SCHEMBL2643816

NC(=O)c1cc(N)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.47
TSHR P16473 1/20 0.47
MC4R P32245 1/20 0.47
ADRA1A P35348 1/20 0.47
MC3R P41968 1/20 0.47
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
KDM5C P41229 2/20 0.41
KDM5B Q9UGL1 2/20 0.41
KDM4B O94953 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
KDM6B O15054 1/20 0.41
TET3 O43151 1/20 0.41
KDM4A O75164 1/20 0.41
BBOX1 O75936 1/20 0.41
KDM5A P29375 1/20 0.41
ASPH Q12797 1/20 0.41
KDM4D Q6B0I6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40990 0.83 KDM4E (0.61) KDM5CKDM5BKDM4BKDM4EALDH1A1
SCHEMBL29452923 0.83 KDM4E (0.61) KDM5CKDM5BKDM4BKDM4EALDH1A1
SCHEMBL2643345 0.81 ALDH1A1 (0.50) MKNK1MKNK2KDM5CKDM5BKDM4E
SCHEMBL796861 0.81 KDM4E (0.59) KDM5CKDM5BKDM4BKDM4EALDH1A1
SCHEMBL7064288 0.80 MKNK1 (0.57) ADORA3TSHRMC4RADRA1AMC3R
Hydrochloric Acid SCHEMBL9792812 0.80 MKNK1 (0.52) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL159513 0.78 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL2644294 0.78 ADORA3 (0.47) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL608325 0.78 KDM5C (0.55) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL17984756 0.78 PRSS1 (0.41) TSHRMKNK1MKNK2KDM5CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375549-A Method and system for synthesizing amide compound from nitrile compound 深圳湾实验室 2023-07-04 CN claimed
US-12441703-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-10-14 US disclosed
US-20250213555-A1 SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-07-03 US disclosed
WO-2025092922-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF IONGEN THERAPEUTICS CO., LTD. (CN) 2025-05-08 WO disclosed
WO-2025092901-A1 NOVEL COMPOUNDS AS MODULATORS OF SODIUM CHANNELS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2025-05-08 WO disclosed
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2025-04-10 US disclosed
CN-119731169-A Sodium channel regulator and application thereof 上海汇伦医药股份有限公司 2025-03-28 CN disclosed
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-13 US disclosed
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2025-01-14 US disclosed
US-7629362-B2 2-pyridine carboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
CN-101500993-A 2-aminocarbonylphenylamino-2-phenylacetamides as factor VIIa inhibitors useful as anticoagulants BRISTOL MYERS SQUIBB CO (US) 2009-08-05 CN disclosed
EP-2061756-A2 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2009-05-27 EP disclosed
WO-2009012375-A2 SQUARATE KINASE INHIBITORS WYETH (US) 2009-01-22 WO disclosed
WO-2007146719-A2 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-21 WO disclosed
WO-2007146719-A2 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-21 WO disclosed
US-20060293503-A1 Polyaminopyridines and method for producing same SUMITOMO SEIKA CHEMICALS CO., LTD (JP) 2006-12-28 US disclosed
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 US disclosed
EP-1669390-A1 POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2006-06-14 EP disclosed
EP-1598349-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195445-B2 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors SCN8A, SCN2A, SCN1A ADORA3 578/4885TSHR 4084/4885MC4R 1113/4885
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN1A ADORA3 578/4885TSHR 4084/4885MC4R 1113/4885
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF SCN8A, SCN10A, SCN7A ADORA3 3076/4885TSHR 3433/4885MC4R 1584/4885
US-12441703-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ADORA3 721/4885TSHR 3163/4885MC4R 1129/4885
US-20250213555-A1 SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN1A, TRPA1 ADORA3 1259/4885TSHR 3356/4885MC4R 1577/4885
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives GCKR, GCK, HK2 ADORA3 760/4885TSHR 2160/4885MC4R 730/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ADORA3 721/4885TSHR 3163/4885MC4R 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.